Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Latest News

MannKind (MNKD) Following Furoscix Approval, Buying Opportunity Or Already Priced In?

Simply Wall St. • 07/25/2026

MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks

Simply Wall St. • 07/25/2026

How Investors May Respond To MannKind (MNKD) Winning FDA Approval For At‑Home Furoscix Autoinjector

Simply Wall St. • 07/25/2026

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost

Stocktwits • 07/24/2026

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MT Newswires • 07/24/2026